- GOP hopes taking shutdown off the table with budget deal will pay dividends
- Chinese Death Star: The moon cited as the perfect launch pad for ballistic missiles
- Help wanted: Homeland Security plagued by vacancies at the top
- We are not amused: Queen’s protection officers warned to keep ‘sticky fingers’ off the royal cashews
- Unleash the crossbows: Gov. Scott Walker creates new hunting season
- Bubonic plague kills 20 in Madagascar
- G-20 diplomats fell for hacker attack promising nude photos of former French first lady Carla Bruni
- Minnesota guardsman charged with stealing private soldier data for fake IDs
- Florida appeals court rules universities can’t regulate guns
- Vladimir Putin defends Russian conservative values
Supreme Court: Companies cannot obtain patents for human genes
Ruling could allow broader research
The Supreme Court on Thursday ruled unanimously that human genes are “a product of nature” and companies cannot obtain patents on them — a major shift in patent policy that could open the door to broader medical research on certain cancers and other diseases.
The decision threw out patents awarded to Myriad Genetics Inc., a Utah firm that isolated the location and sequence of what’s known as the BRCA gene, which can signal risk of developing breast and ovarian cancer.
But the ruling also held that genes the companies create themselves, which Myriad call cDNA, can be patented. The high court left the door open to Myriad and other companies that seek patents for the methods they employ to manipulate genes.
Advocates said prohibiting patents of genes could make tests more affordable by spurring competition among entities that want to test for high-risk gene mutations.
Actress Angelina Jolie recently called attention to the issue by having a preventive double mastectomy because she carries the mutated gene that makes her highly vulnerable to breast cancer.
Myriad’s shares soared Thursday immediately after the ruling but took a dive later in the day, an indication that investors were still trying to digest the mixed ruling. In a statement, the Salt Lake City company highlighted court’s ruling that engineered genes could be patented.
“We believe the court appropriately upheld our claims on cDNA, and underscored the patent eligibility of our method claims, ensuring strong intellectual property protection for our test moving forward,” Myriad President and CEO Peter D. Meldrum said.
But the Association for Molecular Pathology, the lead petitioners in the case against Myriad, also hailed the decision as a boon for scientific research.
“The Court’s decision that human genes are not patentable is a great step forward for the field of molecular pathology, for genomic science, and most important for our patients,” the group said.
Justice Thomas‘ opinion, underscoring the esoteric nature of the topic, was heavy with jargon such as “eons,” “messenger RNA” and “nucleotides.” It also delved into the history of human genome research and the “double-helix” that British researchers James Watson and Francis Crick first mapped in 1953.
Justice Antonin Scalia filed a concurring opinion saying he was unable to get into the “fine details of molecular biology” but was confident the DNA that Myriad isolated is identical to the material in its natural state, so it cannot be patented.
Mary Anthony Merchant, a patents specialist at the Ballard Spahr law firm’s Atlanta office, said the court’s interpretation of what it means to isolate something from nature could produce a “ripple effect” among patents on products derived from naturally occurring substances.
“That word ‘isolated’ was kind of magic language at the patent office,” she said. “It was implied, in ‘isolated,’ that you were doing something to do it.”
Various interest groups, including ones that often do not see eye to eye, reacted positively to the court’s decision.
© Copyright 2013 The Washington Times, LLC. Click here for reprint permission.
About the Author
Tom Howell Jr. covers politics for The Washington Times. He can be reached at email@example.com.
- In rare bipartisan move, Congress tackles long-standing Medicare issue
- White House improvises again on patchy Obamacare rollout
- Key Obamacare official: Last two months much harder than anyone hoped
- HHS Secretary Kathleen Sebelius calls for review of Obamacare rollout woes
- More than a quarter million sign up for Obamacare in November
Latest Blog Entries
- Calif.: Give 'gift of health' by pledging cash for the uninsured
- Tensions hit boiling point over Obamacare enrollment figures, error rates
- Young, uninsured adults vital to Obamacare are not keen on enrolling: New Harvard poll
- Paul Bunyan and Babe the Blue Ox will promote Obamacare at Mall of America
- HealthCare.gov employs a new look once again
By Mangosuthu Buthelezi
Memories of a long brotherhood tempered in common struggle
- NAPOLITANO: A conspiracy so vast
- Comma on!: Twitter erupts over Obama-Castro 'marriage'
- Obama's Afghanistan experts stumped on U.S. death toll, war costs during hearing
- Biden guarantees victory on immigration reform
- House votes for bargain to end budget drama
- Jane Fonda Foundation fails to make single contribution in 5 years: report
- Obama takes 'selfie' at Mandela's funeral service
- Spike in battlefield deaths linked to restrictive rules of engagement
- Atheists smug as Hindus join Satanists to demand display at Oklahoma Statehouse
- American bourbon now better than Scottish whisky: U.K.-born expert
Independent voices from the The Washington Times Communities
Consummate traveler Todd DeFeo explores the unique stories that make destinations worth going to.
Covering the world of soccer, including the World Cup, Major League Soccer, D.C. United and the English Premier League and other interesting sporting events.
Born in 1930 in rural Missouri, Charles Vandegriffe, Sr., brings his time and place to the Communities.
Columns from Voices around the World talking about the events, people, politics and social issues that concern us wherever, and whoever, we are.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow